Currently Recruiting Trials – Pediatric Glioma

Last page update: June 12, 2017

New Trials (added here in the last month)

High Grade pediatric glioma including Diffuse intrinsic pontine glioma

Vaccines

A Phase I and Feasibility Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine for Pediatric Patients With Newly Diagnosed Intracranial High Grade Glioma and Recurrent Resectable Intracranial High Grade Glioma and Ependymoma. Ages 3-21. Chicago IL. Estimated primary completion date: May 2018.
NCT02722512

A Pilot Study to Evaluate the Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides With Poly-ICLC for Children With Newly Diagnosed Malignant Brain Stem Gliomas, Non-Brainstem High-Grade Gliomas, Recurrent Low-Grade Gliomas or Recurrent High Grade Gliomas. Ages 1-21 years. Pittsburgh PA. Estimated primary completion date: February 2017.
NCT01130077

Dendritic Cell Vaccine For Malignant Glioma and Glioblastoma Multiforme in Adult and Pediatric Subjects. Ages 13 and older. Miami FL. Estimated primary completion date: July 2018.
NCT01808820

Phase Ib Clinical Trial on the Safety of Immunotherapy With Autologous Dendritic Cells Primed With Lysate Allogeneic Tumor Lines in Patients With Diffuse Intrinsic Pontine Glioma (DIPG). Ages 3-18. Spain. Estimated primary completion date: March 2019.
NCT02840123

H3.3K27M Specific Peptide Vaccine Combined With Poly-ICLC for the Treatment of Newly Diagnosed HLA-A2+ H3.3K27M Positive Diffuse Intrinsic Pontine Glioma (DIPG) as Well as Other Newly Diagnosed HLA-A2+ H3.3K27M Positive Gliomas. University of California, San Francisco. Ages 3-21. Study start date: November 2016. Estimated primary completion date: November 2019.
NCT02960230

Immune checkpoint inhibitors

A Safety and Preliminary Efficacy Trial of Pembrolizumab (MK-3475; Anti-PD-1) in Children With Recurrent, Progressive or Refractory High-Grade Gliomas (HGG) and DIPGs. Memphis TN. Estimated primary completion date: April 2018.
NCT02359565

Virotherapy and virally delivered therapies

Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children With Recurrent Supratentorial Brain Tumors. Ages 3-18. Birmingham AL. Estimated primary completion date: May 2019.
NCT02457845

Phase 1 Study of Replication Competent Reovirus (Reolysin®) in Combination With GM-CSF in Pediatric Patients With Relapsed or Refractory Brain Tumors. Ages 10-21. Mayo Clinic, Rochester MN. Study start date: May 2015. Estimated primary completion date: April 2020.
NCT02444546

Other Notable trials

Photodynamic Therapy (PDT) for Recurrent Pediatric Brain Tumors. Ages 6 months – 18 years. Children’s Hospital of Wisconsin USA. Estimated primary completion date: April 2019.
NCT01682746

Phase 1 Trial of Panobinostat in Children With Diffuse Intrinsic Pontine Glioma. Ages 2-21. Multiple centers across the US in CA, DC, IL, MD, NY, OH, PA, TN, TX. Estimated primary completion date: February 2019.
NCT02717455

A Pilot Trial Testing the Feasibility of Using Molecular Profiling to Guide an Individualized Treatment Plan in Children and Young Adults With Newly Diagnosed DIPG. Ages up to 25. San Francisco CA. Estimated primary completion date: May 2017.
NCT02274987

A Phase I Study of Convection-Enhanced Delivery of 124I-8H9 for Patients With Non-Progressive Diffuse Pontine Gliomas Previously Treated With External Beam Radiation Therapy. Ages 3-21. New York NY. Estimated primary completion date: December 2017.
NCT01502917

Low grade pediatric glioma

Pilot Efficacy Study of Vemurafenib, an Oral Inhibitor of BRAFV600E, in Children With Recurrent/Refractory BRAFV600E-mutant Gliomas. Los Angeles CA, Oakland CA, San Diego CA, San Francisco CA, District of Columbia, Portland OR, Philadelphia PA, Memphis TN, Salt Lake City UT, Seattle WA. Estimated primary completion date: January 2017.
NCT01748149

A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation. Boston, MA. Estimated primary completion date: January 2020. Ages 1-25.
NCT01288235

A Phase II Study of Vaccinations With HLA-A2 Restricted Glioma Antigen Peptides in Combination With Poly-ICLC for Children With Recurrent Unresectable Low-Grade Gliomas. Pittsburgh PA. Estimated primary completion date: January 2020.
NCT02358187

A Phase II Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas. Ages 0-21. San Diego CA, Atlanta GA. Estimated primary completion date: December 2016.
NCT01188096

Leah’s story

September 2014. 4-year old Leah Merklin’s parents have stabilized their daughters diffuse intrinsic pontine glioma by giving the child small amounts of cannabis oil sandwiched between Cheerios three times daily. Diagnosed on April 24, 2013, the girl was given 6-12 months to live. Cannabis oil treatment began in July 2013, leading to greatly improved quality of life. There was no growth from January – July 2014, the time of the last brain scan. Watch the NBC news story.

April 2015
Leah blew out the candles on her fifth birthday cake on March 31, 2015. “We don’t plan on her treatment changing at all as marijuana becomes legal [in Oregon]. There are so many facets at play and many things may change, but Leah’s treatment is not one of them. Cannabis oil has saved her life thus far, and we will not be stopping it any time soon,” Merklin said.
Source

August 2015
The early August MRI showed Leah’s tumor to remain stable, now 2 years and 4 months from diagnosis.